Cancer Gene Therapy

Companies Will Develop Cell-Based Therapies

Published in Gene Therapy Weekly, February 21st, 2002

Schering AG of Berlin and Mologen, a biotechnology corporation also located in Berlin, Germany, signed a contract to develop cell-based therapies by using Mologen's MIDGE technology. Among the development goals are cell-based treatments of cancer.

Mologen-owned MIDGE technology provides Schering AG with a safe and efficient DNA vector system. MIDGE may transfer into the cells of patients to deliver gene information, e.g., for the treatment of cancers or the regeneration of tissues. A third party in the project is SynerGene Therapeutics, Inc., located in Washington, DC, which also develops solutions for targeted delivery of therapeutics. By combining both...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2002-02-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry